Lyrica Receives CHMP Opinion For The Treatment Of Generalized Anxiety Disorder In Adults June 6, 2009
Pfizer Inc said today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorization of Lyrica